Accelerate Diagnostics sees FY 2019 revenue as high as $9.3M

Accelerate Diagnostics (NASDAQ:AXDX) reports preliminary financial results for Q4 and FY 2019.

Commercially contracted instruments were 137 in Q4 and 304 for FY 2019.

Total revenue for Q4 and FY 2019 is expected to be ~$3.5M and $9.3M, respectively.

FY 2019 Gross margin is expected to be roughly 50%.

Net cash used is expected to be ~$58M for FY 2019.

Full audited financial results for Q4 and FY 2019 will be filed in late February.

#JPM20

https://seekingalpha.com/news/3531165-accelerate-diagnostics-sees-fy-2019-revenue-high-9_3m